Investigation of the metabolic and endocrinological differences between daily and weekly growth hormone replacement therapy, somapacitan, in patients with adult growth hormone deficiency: A real-world pilot study.

Abe I, Takeshita K, Nagata M, Fujita Y, Ochi K, Koga M, Kudo T, Shimada H, Abe M, Mukoubara S, Kobayashi K

Medicine1 Sept 2023Cited by 4 (Europe PMC)

PMID37746989PMCIDPMC10519569DOI10.1097/md.0000000000034730PepBankPUB-37746989

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with GHD, switching to somapacitan was linked to improved BMI at 6 months versus switching baseline (P < .05).
In plain wordsIn adults with GHD, switching to somapacitan was linked to improved BMI after 6 months compared with baseline.
Peptide
Somapacitan
Outcome
Direction not reportedBMI
Study
n = 11
Comparator
At switching from daily GH
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and liver functions were significantly improved 6 months after switching compared to those at switching (each P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698901
02HumanObservational studyEfficacy outcome
In adults with GHD, switching to somapacitan was linked to improved HOMA-IR at 6 months versus switching baseline (P < .05).
In plain wordsIn adults with GHD, switching to somapacitan was linked to improved insulin resistance after 6 months compared with baseline.
Peptide
Somapacitan
Outcome
Direction not reportedHOMA-IR
Study
n = 11
Comparator
At switching from daily GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and liver functions were significantly improved 6 months after switching compared to those at switching (each P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698902
03HumanObservational studyEfficacy outcome
In adults with GHD, switching to somapacitan was linked to improved FPG at 6 months versus switching baseline (P < .05).
In plain wordsIn adults with GHD, switching to somapacitan was linked to improved fasting blood sugar after 6 months compared with baseline.
Peptide
Somapacitan
Outcome
Direction not reportedFPG
Study
n = 11
Comparator
At switching from daily GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and liver functions were significantly improved 6 months after switching compared to those at switching (each P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698903
04HumanObservational studyEfficacy outcome
In adults with GHD, switching to somapacitan was linked to improved liver functions at 6 months versus switching baseline (P < .05).
In plain wordsIn adults with GHD, switching to somapacitan was linked to improved liver function after 6 months compared with baseline.
Peptide
Somapacitan
Outcome
Direction not reportedLiver functions
Study
n = 11
Comparator
At switching from daily GH
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and liver functions were significantly improved 6 months after switching compared to those at switching (each P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698904
05HumanObservational studyOther
In adults switching to somapacitan, HOMA-IR improvement was linked to prior daily GH duration (P = .048).
In plain wordsIn adults switching to somapacitan, insulin resistance improvement was linked to the duration of prior daily GH treatment.
Peptide
Somapacitan
Outcome
Direction not reportedPrior daily GH duration and HOMA-IR improvement
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Besides, the improvement in HOMA-IR was significantly associated with the period of daily GH replacement therapy before switching (P = .048),
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698905
06HumanObservational studyOther
In adults switching to somapacitan, other listed covariate associations with HOMA-IR improvement had P > .05.
In plain wordsIn adults switching to somapacitan, other listed factors had no statistically significant association with insulin resistance improvement.
Peptide
Somapacitan
Outcome
No significant changeOther covariates and HOMA-IR improvement
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
while age, sex, improvement in BMI or liver functions, presence of any hormonal deficiency, and the existence of any hormonal replacement therapy significantly associated (P > .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698906
07HumanObservational studyEfficacy outcome
In adults with GHD, switching from daily GH to somapacitan did not affect endocrinological parameters.
In plain wordsIn adults with GHD, switching from daily GH to somapacitan was not linked to changes in hormone measurements.
Peptide
Somapacitan
Outcome
No significant changeEndocrinological parameters
Study
n = 11
Comparator
At switching from daily GH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, switching to GH replacement therapy did not affect endocrinological parameters.
3 context sentences(design, population, supporting numbers)
Summary · context
In this real-world pilot study, we evaluated the metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy using somapacitan.
Summary · context
Eleven patients with AGHD, whose medical treatment aside from GH replacement therapy did not change, were enrolled.
Summary · context
We investigated the metabolic and endocrinological parameters between at switching and 6 months after switching from daily GH formulation to somapacitan.
Report a problemFND-3774698907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.